Bavarian Nordic
Headquarters country
Denmark
Registry sponsor category
Industry
- Other names
- Bavarian Nordic
- Company name
- Bavarian Nordic
- Organisation type
- Industry
- Registered legal name
- BAVARIAN NORDIC A/S
- Registry sponsor category
- Industry
- Website
- https://www.bavarian-nordic.com
- Legal Entity Identifier (LEI)
- 2138006JCDVYIN6INP51
- Wikidata ID
- Q812002
Related records
Trials (70)
- A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®
- A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer
- A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine
- A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults
- A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
- A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis
- A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects
- A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
- A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects
- A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
- A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy
- A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer
- A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer
- A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults
- A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine
- A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects
- A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
- A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC
- A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects
- ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2